FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2901992912> ?p ?o ?g. }

• W2901992912 endingPage "k4880" @default.
• W2901992912 startingPage "k4880" @default.
• W2901992912 abstract "Abstract Objective To determine whether use of dipeptidyl peptidase-4 (DPP-4) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists are associated with an increased risk of cholangiocarcinoma in adults with type 2 diabetes. Design Population based cohort study. Setting General practices contributing data to the UK Clinical Practice Research Datalink. Participants 154 162 adults newly treated with antidiabetic drugs between 1 January 2007 and 31 March 2017, followed until 31 March 2018. Main outcome measures Use of DPP-4 inhibitors and GLP-1 receptor agonists was modelled as a time varying variable and compared with use of other second or third line antidiabetic drugs. All exposures were lagged by one year to account for cancer latency and to minimise reverse causality. Cox proportional hazards models were used to estimate hazard ratios and 95% confidence intervals of incident cholangiocarcinoma associated with use of DPP-4 inhibitors and GLP-1 receptor agonists, separately. A post hoc pharmacovigilance analysis was conducted using the World Health Organization’s global individual case safety report database, VigiBase, to estimate reporting odds ratios of cholangiocarcinoma. Results During 614 274 person years of follow-up, 105 incident cholangiocarcinoma events occurred (rate 17.1 per 100 000 person years). Use of DPP-4 inhibitors was associated with a 77% increased hazard of cholangiocarcinoma (hazard ratio 1.77, 95% confidence interval 1.04 to 3.01). Use of GLP-1 receptor agonists was associated with an increased hazard with a wide confidence interval (hazard ratio 1.97, 0.83 to 4.66). In the pharmacovigilance analysis, the use of DPP-4 inhibitors and GLP-1 receptor agonists were both associated with increased reporting odds ratios for cholangiocarcinoma, compared with use of sulfonylureas or thiazolidinediones (1.63, 1.00 to 2.66, 4.73, 2.95 to 7.58, respectively). Conclusion Compared with use of other second or third line antidiabetic drugs, use of DPP-4 inhibitors, and possibly GLP-1 receptor agonists, might be associated with an increased risk of cholangiocarcinoma in adults with type 2 diabetes." @default.
• W2901992912 created "2018-12-11" @default.
• W2901992912 creator A5002024158 @default.
• W2901992912 creator A5016406653 @default.
• W2901992912 creator A5025595526 @default.
• W2901992912 creator A5027339862 @default.
• W2901992912 creator A5028735116 @default.
• W2901992912 creator A5043245206 @default.
• W2901992912 creator A5056419976 @default.
• W2901992912 creator A5072578581 @default.
• W2901992912 creator A5081987341 @default.
• W2901992912 date "2018-12-05" @default.
• W2901992912 modified "2023-10-01" @default.
• W2901992912 title "Incretin based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: population based cohort study" @default.
• W2901992912 cites W1798757189 @default.
• W2901992912 cites W1834728684 @default.
• W2901992912 cites W1977950682 @default.
• W2901992912 cites W1988068931 @default.
• W2901992912 cites W1994320162 @default.
• W2901992912 cites W2009428399 @default.
• W2901992912 cites W2021010531 @default.
• W2901992912 cites W2032414382 @default.
• W2901992912 cites W2038981426 @default.
• W2901992912 cites W2064130493 @default.
• W2901992912 cites W2064716383 @default.
• W2901992912 cites W2077030565 @default.
• W2901992912 cites W2079396916 @default.
• W2901992912 cites W2082081076 @default.
• W2901992912 cites W2102994534 @default.
• W2901992912 cites W2111714917 @default.
• W2901992912 cites W2117674153 @default.
• W2901992912 cites W2118502261 @default.
• W2901992912 cites W2123767664 @default.
• W2901992912 cites W2123844577 @default.
• W2901992912 cites W2127854619 @default.
• W2901992912 cites W2134760433 @default.
• W2901992912 cites W2142830692 @default.
• W2901992912 cites W2160088494 @default.
• W2901992912 cites W2163589808 @default.
• W2901992912 cites W2164595809 @default.
• W2901992912 cites W2167950733 @default.
• W2901992912 cites W2172204314 @default.
• W2901992912 cites W2282578582 @default.
• W2901992912 cites W2283546675 @default.
• W2901992912 cites W2425644022 @default.
• W2901992912 cites W2485875310 @default.
• W2901992912 cites W2519510391 @default.
• W2901992912 cites W2614410423 @default.
• W2901992912 cites W2754041380 @default.
• W2901992912 cites W2767934199 @default.
• W2901992912 cites W2802245520 @default.
• W2901992912 cites W2804322951 @default.
• W2901992912 cites W2807726778 @default.
• W2901992912 cites W2885566454 @default.
• W2901992912 cites W2895691398 @default.
• W2901992912 cites W4211025847 @default.
• W2901992912 cites W4300187280 @default.
• W2901992912 cites W807162506 @default.
• W2901992912 doi "https://doi.org/10.1136/bmj.k4880" @default.
• W2901992912 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6278586" @default.
• W2901992912 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30518618" @default.
• W2901992912 hasPublicationYear "2018" @default.
• W2901992912 type Work @default.
• W2901992912 sameAs 2901992912 @default.
• W2901992912 citedByCount "30" @default.
• W2901992912 countsByYear W29019929122018 @default.
• W2901992912 countsByYear W29019929122019 @default.
• W2901992912 countsByYear W29019929122020 @default.
• W2901992912 countsByYear W29019929122021 @default.
• W2901992912 countsByYear W29019929122022 @default.
• W2901992912 countsByYear W29019929122023 @default.
• W2901992912 crossrefType "journal-article" @default.
• W2901992912 hasAuthorship W2901992912A5002024158 @default.
• W2901992912 hasAuthorship W2901992912A5016406653 @default.
• W2901992912 hasAuthorship W2901992912A5025595526 @default.
• W2901992912 hasAuthorship W2901992912A5027339862 @default.
• W2901992912 hasAuthorship W2901992912A5028735116 @default.
• W2901992912 hasAuthorship W2901992912A5043245206 @default.
• W2901992912 hasAuthorship W2901992912A5056419976 @default.
• W2901992912 hasAuthorship W2901992912A5072578581 @default.
• W2901992912 hasAuthorship W2901992912A5081987341 @default.
• W2901992912 hasBestOaLocation W29019929121 @default.
• W2901992912 hasConcept C126322002 @default.
• W2901992912 hasConcept C134018914 @default.
• W2901992912 hasConcept C143998085 @default.
• W2901992912 hasConcept C156490143 @default.
• W2901992912 hasConcept C156957248 @default.
• W2901992912 hasConcept C201903717 @default.
• W2901992912 hasConcept C207103383 @default.
• W2901992912 hasConcept C23276603 @default.
• W2901992912 hasConcept C2426938 @default.
• W2901992912 hasConcept C2776865356 @default.
• W2901992912 hasConcept C2777180221 @default.
• W2901992912 hasConcept C2780035454 @default.
• W2901992912 hasConcept C2908647359 @default.
• W2901992912 hasConcept C44249647 @default.
• W2901992912 hasConcept C50382708 @default.
• W2901992912 hasConcept C555293320 @default.

• next